Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of An2 Therapeutics, Inc. (ANTX) since 2022 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of An2 Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1880438.
Total stock buying since 2022: $51,259,932.
Total stock sales since 2022: $18,733,609.
Total stock option exercises since 2022: $27,117.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 18,610 | $20,803 | 2,949,606 | $3,336,679 | 0 | $0 |
| 2024 | 1,910,000 | $2,040,536 | 3,842,965 | $10,017,309 | 10,000 | $27,117 |
| 2023 | 1,787,778 | $16,053,772 | 238,403 | $3,872,746 | 0 | $0 |
| 2022 | 2,260,186 | $33,144,821 | 94,231 | $1,506,875 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 10,000 | $10,670 | 0 | $0 | 0 | $0 |
| 2025-05 | 8,610 | $10,133 | 2,932,000 | $3,313,071 | 0 | $0 |
| 2025-01 | 0 | $0 | 17,606 | $23,608 | 0 | $0 |
| 2024-12 | 60,000 | $86,736 | 0 | $0 | 0 | $0 |
| 2024-11 | 350,000 | $393,800 | 0 | $0 | 0 | $0 |
| 2024-08 | 1,500,000 | $1,560,000 | 3,525,094 | $3,807,101 | 0 | $0 |
| 2024-01 | 0 | $0 | 317,871 | $6,210,208 | 10,000 | $27,117 |
| 2023-11 | 0 | $0 | 3,620 | $58,448 | 0 | $0 |
| 2023-10 | 0 | $0 | 11,344 | $182,298 | 0 | $0 |
| 2023-09 | 0 | $0 | 222,639 | $3,619,200 | 0 | $0 |
| 2023-08 | 1,777,778 | $16,000,002 | 800 | $12,800 | 0 | $0 |
| 2023-05 | 10,000 | $53,770 | 0 | $0 | 0 | $0 |
| 2022-11 | 0 | $0 | 58,342 | $924,176 | 0 | $0 |
| 2022-10 | 0 | $0 | 35,889 | $582,699 | 0 | $0 |
| 2022-08 | 1,909 | $14,330 | 0 | $0 | 0 | $0 |
| 2022-07 | 23,219 | $180,673 | 0 | $0 | 0 | $0 |
| 2022-06 | 81,726 | $649,838 | 0 | $0 | 0 | $0 |
| 2022-03 | 2,153,332 | $32,299,980 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-02 | Easom Eric (Chief Executive Officer) | Buy | 10,000 | 1.07 | 10,670 |
| 2025-05-30 | Leonard Braden Michael | Sale | 432,000 | 1.02 | 441,071 |
| 2025-05-28 | Fitzpatrick Margaret M | Buy | 8,610 | 1.18 | 10,133 |
| 2025-05-28 | Leonard Braden Michael | Sale | 2,300,000 | 1.12 | 2,654,000 |
| 2025-01-03 | Prior Stephen David (Chief Strategy Officer) | Sale | 2,029 | 1.34 | 2,720 |
| 2025-01-03 | Eizen Joshua M (See Remarks) | Sale | 9,663 | 1.34 | 12,958 |
| 2025-01-03 | Day Lucy (Chief Financial Officer) | Sale | 2,957 | 1.34 | 3,965 |
| 2025-01-03 | Chanda Sanjay (Chief Development Officer) | Sale | 2,957 | 1.34 | 3,965 |
| 2024-12-10 | Readnour Robin Shane | Buy | 10,000 | 1.49 | 14,930 |
| 2024-12-09 | Readnour Robin Shane | Buy | 30,772 | 1.43 | 44,003 |
| 2024-12-06 | Readnour Robin Shane | Buy | 19,228 | 1.45 | 27,803 |
| 2024-11-27 | Readnour Robin Shane | Buy | 50,000 | 1.42 | 70,850 |
| 2024-11-26 | Readnour Robin Shane | Buy | 25,000 | 1.39 | 34,850 |
| 2024-11-20 | Readnour Robin Shane | Buy | 50,000 | 1.16 | 57,850 |
| 2024-11-19 | Readnour Robin Shane | Buy | 150,000 | 1.03 | 155,250 |
| 2024-11-19 | Zakrzewski Joseph S | Buy | 5,000 | 1.01 | 5,050 |
| 2024-11-18 | Easom Eric (Chief Executive Officer) | Buy | 50,000 | 1.00 | 49,950 |
| 2024-11-18 | Zakrzewski Joseph S | Buy | 20,000 | 1.00 | 20,000 |
| 2024-08-14 | Leonard Braden Michael | Buy | 1,500,000 | 1.04 | 1,560,000 |
| 2024-08-09 | Shah Rajeev M. | Sale | 3,525,094 | 1.08 | 3,807,101 |
| 2024-01-18 | Zakrzewski Joseph S | Sale | 100,000 | 19.11 | 1,911,400 |
| 2024-01-16 | Adjuvant Capital Management, Llc | Sale | 100,000 | 19.65 | 1,964,999 |
| 2024-01-16 | Aziz Kabeer | Sale | 100,000 | 19.65 | 1,964,999 |
| 2024-01-12 | Readnour Robin Shane (Director) | Sale | 1,425 | 21.91 | 31,228 |
| 2024-01-10 | Readnour Robin Shane (Director) | Sale | 3,669 | 21.93 | 80,442 |
| 2024-01-09 | Krause Kevin Michael (Chief Strategy Officer) | Sale | 7,417 | 20.14 | 149,370 |
| 2024-01-09 | Krause Kevin Michael (Chief Strategy Officer) | Option Ex | 7,417 | 3.51 | 26,033 |
| 2024-01-02 | Krause Kevin Michael (Chief Strategy Officer) | Sale | 2,583 | 20.12 | 51,967 |
| 2024-01-02 | Krause Kevin Michael (Chief Strategy Officer) | Option Ex | 2,583 | .42 | 1,084 |
| 2024-01-02 | Easom Eric (Chief Executive Officer) | Sale | 2,777 | 20.09 | 55,803 |
| 2023-11-14 | Adjuvant Capital Management, Llc | Sale | 1,810 | 16.15 | 29,224 |
| 2023-11-14 | Aziz Kabeer | Sale | 1,810 | 16.15 | 29,224 |
| 2023-10-02 | Adjuvant Capital Management, Llc | Sale | 5,672 | 16.07 | 91,149 |
| 2023-10-02 | Aziz Kabeer | Sale | 5,672 | 16.07 | 91,149 |
| 2023-09-29 | Adjuvant Capital Management, Llc | Sale | 99,101 | 16.28 | 1,613,364 |
| 2023-09-29 | Aziz Kabeer | Sale | 99,101 | 16.28 | 1,613,364 |
| 2023-09-28 | Adjuvant Capital Management, Llc | Sale | 8,516 | 16.11 | 137,192 |
| 2023-09-27 | Adjuvant Capital Management, Llc | Sale | 841 | 16.07 | 13,514 |
| 2023-09-13 | Adjuvant Capital Management, Llc | Sale | 400 | 16.00 | 6,400 |
| 2023-09-13 | Aziz Kabeer | Sale | 400 | 16.00 | 6,400 |
| 2023-09-07 | Adjuvant Capital Management, Llc | Sale | 3,378 | 16.05 | 54,216 |
| 2023-09-07 | Aziz Kabeer | Sale | 3,378 | 16.05 | 54,216 |
| 2023-09-06 | Adjuvant Capital Management, Llc | Sale | 3,762 | 16.02 | 60,267 |
| 2023-09-06 | Aziz Kabeer | Sale | 3,762 | 16.02 | 60,267 |
| 2023-08-23 | Adjuvant Capital Management, Llc | Sale | 400 | 16.00 | 6,400 |
| 2023-08-23 | Aziz Kabeer | Sale | 400 | 16.00 | 6,400 |
| 2023-08-18 | Shah Rajeev M. | Buy | 1,777,778 | 9.00 | 16,000,002 |
| 2023-05-15 | Easom Eric (Chief Executive Officer) | Buy | 10,000 | 5.38 | 53,770 |
| 2022-11-14 | Easom Eric (Chief Executive Officer) | Sale | 23 | 15.04 | 345 |
| 2022-11-10 | Easom Eric (Chief Executive Officer) | Sale | 4,413 | 15.32 | 67,629 |
| 2022-11-09 | Easom Eric (Chief Executive Officer) | Sale | 10,111 | 15.61 | 157,842 |
| 2022-11-08 | Easom Eric (Chief Executive Officer) | Sale | 7,055 | 15.90 | 112,153 |
| 2022-11-07 | Easom Eric (Chief Executive Officer) | Sale | 12,203 | 16.31 | 199,043 |
| 2022-11-04 | Easom Eric (Chief Executive Officer) | Sale | 8,828 | 15.80 | 139,473 |
| 2022-11-03 | Easom Eric (Chief Executive Officer) | Sale | 14,165 | 15.84 | 224,430 |
| 2022-11-02 | Easom Eric (Chief Executive Officer) | Sale | 1,544 | 15.07 | 23,261 |
| 2022-10-31 | Easom Eric (Chief Executive Officer) | Sale | 2,688 | 15.39 | 41,362 |
| 2022-10-28 | Easom Eric (Chief Executive Officer) | Sale | 1,683 | 15.09 | 25,393 |
| 2022-10-27 | Easom Eric (Chief Executive Officer) | Sale | 924 | 15.36 | 14,189 |
| 2022-10-26 | Easom Eric (Chief Executive Officer) | Sale | 1,678 | 15.10 | 25,342 |
| 2022-10-25 | Easom Eric (Chief Executive Officer) | Sale | 4,806 | 15.95 | 76,631 |
| 2022-10-24 | Easom Eric (Chief Executive Officer) | Sale | 2,866 | 16.17 | 46,343 |
| 2022-10-21 | Easom Eric (Chief Executive Officer) | Sale | 13,951 | 16.49 | 230,093 |
| 2022-10-20 | Easom Eric (Chief Executive Officer) | Sale | 7,293 | 16.91 | 123,346 |
| 2022-08-04 | Shah Rajeev M. | Buy | 100 | 7.99 | 799 |
| 2022-08-03 | Shah Rajeev M. | Buy | 1,809 | 7.48 | 13,531 |
| 2022-07-27 | Shah Rajeev M. | Buy | 8,281 | 7.91 | 65,502 |
| 2022-07-26 | Shah Rajeev M. | Buy | 14,938 | 7.71 | 115,171 |
| 2022-06-21 | Shah Rajeev M. | Buy | 302 | 7.99 | 2,412 |
| 2022-06-14 | Shah Rajeev M. | Buy | 61,424 | 7.97 | 489,426 |
| 2022-06-13 | Shah Rajeev M. | Buy | 20,000 | 7.90 | 158,000 |
| 2022-03-29 | Readnour Robin Shane (Director) | Buy | 153,334 | 15.00 | 2,300,010 |
| 2022-03-29 | Aziz Kabeer (Director) | Buy | 166,666 | 15.00 | 2,499,990 |
| 2022-03-29 | Adjuvant Global Health Technology Fund De, L.p. (10% Owner) | Buy | 166,666 | 15.00 | 2,499,990 |
| 2022-03-29 | Shah Rajeev M. | Buy | 1,666,666 | 15.00 | 24,999,990 |
Insider trading activities including stock purchases, stock sales, and option exercises of ANTX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of An2 Therapeutics, Inc. (symbol ANTX, CIK number 1880438) see the Securities and Exchange Commission (SEC) website.